Associate Professor
City of Hope National Comprehensive Cancer Center
I am Michael Rosenzweig, MD, an Associate Professor at the Judy Bernard Briskin Center for Multiple Myeloma Research at City of Hope. As a clinical investigator for who cares for patients with both multiple myeloma, I am committed to providing excellent care for my patients but also moving the field forward and improving outcomes. I am the PI of two investigator initiated trials for multiple myeloma with the goal of repurposing leflunomide in both the relapsed refractory and high-risk smoldering myeloma settings. Diversity and inclusion has been a focus of my work on leflunomide and we earned a RO1 from the NIH to specifically investigate leflunomide for African American patients with high risk smoldering disease. In the relapsed setting, I am the PI of a trial that exploits the synergistic effects of leflunomide and pomalidomide with a combination study that has shown promising early results. I also lead the amyloidosis efforts at City of Hope for both transthyretin (TTR) and light chain (AL) amyloidosis. I am the PI for a study exploring venetoclax, ixazomib and dexamethasone for patients with relapsed or refractory AL amyloidosis. Together with my cardiology colleagues, we earned a grant to explore early echocardiographic changes as a potential new diagnostic tool for AL amyloidosis. We also earned a grant to improve the identification of patients with undiagnosed TTR cardiac amyloidosis. I am the PI of several other industry sponsored trials for AL amyloidosis and I am working closely with my non-clinical, scientist colleagues to develop new immunotherapeutic agents for amyloidosis.